ImmunityBio Revenue and Competitors
Estimated Revenue & Valuation
- ImmunityBio's estimated annual revenue is currently $1.5M per year.
- ImmunityBio's estimated revenue per employee is $2,052
- ImmunityBio's current valuation is $2.7B. (January 2022)
Employee Data
- ImmunityBio has 726 Employees.
- ImmunityBio grew their employee count by 4% last year.
ImmunityBio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Chief Accounting Officer (CAO) | Reveal Email/Phone |
3 | Executive Assistant to CFO, General Counsel, SVP Human Resources | Reveal Email/Phone |
4 | Chief Compliance Officer | Reveal Email/Phone |
5 | Chief Compliance Officer | Reveal Email/Phone |
6 | VP Product Development, Cell Therapy Program | Reveal Email/Phone |
7 | General Counsel and Corporate Secretary | Reveal Email/Phone |
8 | VP, Associate General Counsel, Transactions | Reveal Email/Phone |
9 | Head Computational Biology | Reveal Email/Phone |
10 | SVP, Product Development & Vaccine Programs | Reveal Email/Phone |
ImmunityBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is ImmunityBio?
Leading late-stage immunotherapy company harnessing immunogenic cell death by orchestrating both the innate (NK) and adaptive (T Cell) immune system through first-in-class immunological platforms. ImmunityBio (formerly NantCell) develops novel combinations of chemo-immune sensitizers, cell therapies, cytokines, vaccines, neoepitopes, and monoclonal antibody immunotherapies to orchestrate the NK and T Cell response for cancer and infectious diseases.
keywords:N/A
N/A
Total Funding
726
Number of Employees
$1.5M
Revenue (est)
4%
Employee Growth %
$2.7B
Valuation
N/A
Accelerator
ImmunityBio News
Data from ImmunityBio's QUILT 3.032 BCG-unresponsive non-muscle invasive bladder cancer trial will be presented by principal investigator in...
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung...
ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune...
Other Companies in Culver City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $290M | 751 | -2% | $499M |
#2 | $243.2M | 762 | 19% | N/A |
#3 | $15M | 898 | 9% | N/A |
#4 | $271.5M | 960 | 34% | N/A |
#5 | $392.4M | 1038 | 10% | N/A |